Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company, announced that it has received a clearance from the National Medical Products Administration of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep in combination with paclitaxel in patients with advanced/ metastatic breast cancer in China.
March 21, 2019
· 3 min read